Publications
5600 Results
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 9014); ASCO (5/31/19-6/4/19, Chicago IL), poster discussion
- Year
- 2019
- Research Committee(s)
- Lung
- Study Number(s)
- S1400I
A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).
- Journal / Conference
- J Clin Oncol 37(suppl; abstr TPS6652); American Society of Clinical Oncology (5/31/19-6/4/19, Chicago IL), TIPS, poster session
- Year
- 2019
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S1417CD
Design and Accrual of SWOG S1417CD: Development of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer (mCRC)
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 9021); American Society of Clinical Oncology (5/31/19-6/4/19, Chicago IL), poster discussion
- Year
- 2019
- Research Committee(s)
- Lung
- Study Number(s)
- S1507
S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC)
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 4137); American Society of Clinical Oncology (5/31/19 - 6/4/19, Chicago IL), poster session
- Year
- 2019
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1505
SWOG S1505: Initial Findings on Eligibility and Neoadjuvant Chemotherapy Experience with mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 4014); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), poster discussion
- Year
- 2019
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1513
Randomized Phase II Study of 2nd Line Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) vs FOLFIRI in Metastatic Pancreatic Cancer (mPC): SWOG S1513
- Journal / Conference
- J Clin Oncol 37(suppl; abstr TPS2658); ASCO (5/31-6/4/2019, Chicago IL), TIPS, poster session
- Year
- 2019
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
SWOG S1609: A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART)
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 11588); American Society of Clinical Oncology (5/31-6/4/2019, Chicago IL), poster session
- Year
- 2019
- Research Committee(s)
- Cancer Care Delivery and Symptom Management and Survivorship
Sex Differences in Adverse Event Reporting in SWOG Chemotherapy, Biologic/Immunotherapy and Targeted Agent Cancer Clinical Trials
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 6604); American Society of Clinical Oncology (5/31-6/4/2019, Chicago IL), poster session
- Year
- 2019
- Research Committee(s)
- Cancer Care Delivery
The Impact of NCI-Sponsored Network Group Clinical Trials on Guideline Care and New Drug Indications
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 11508); American Society of Clinical Oncology (5/31-6/4/2019, Chicago IL), oral
- Year
- 2019
- Research Committee(s)
- Cancer Care Delivery
The Association of Baseline Cardiovascular Risk Factors and Healthcare Utilization and Costs in Elderly Breast Cancer Patients Enrolled in SWOG Clinical Trials
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 4005); American Society of Clinical Oncology (5/31 - 6/4/2019, Chicago IL), oral
- Year
- 2019
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/A021202